FOR IMMEDIATE RELEASE: April 30, 2021
Waltham, MA - Nova Biomedical is pleased to announce the opening of a new sales, service, and distribution subsidiary in Benelux. The new facility demonstrates Nova’s continued growth in the European market and the expansion of Nova’s biotechnology and clinical products in Belgium, the Netherlands and Luxembourg.
Located in ‘s-Hertogenbosch, the office location provides excellent access to all areas of Benelux, allowing the new subsidiary to fully support current business and anticipated future growth. Nova Benelux will provide full sales and service support to the area’s customers.
With the new subsidiary, Nova will directly sell and support the highly successful BioProfile FLEX2 series of cell culture analyzers, as well as introduce the company’s critical care and point-of-care whole blood analyzers. The well-established StatStrip® and StatSensor® line of handheld, POC meter and test strip analyzers provide rapid glucose/ketone, lactate, creatinine, and haemoglobin/haematocrit results at the bedside to support clinical decision making.
The Stat Profile Prime series of blood gas analyzers offer a comprehensive testing menu of up to 22 measured tests including blood gases, electrolytes, metabolites, hematology, and CO-Oximetry, along with an estimated plasma volume calculation. The Prime series integrates maintenance-free cartridge technology for sensors and reagents with new, maintenance-free, non-lysing whole blood CO-Oximetry.
The new subsidiary will also be promoting the recently launched Allegro capillary blood testing system which is designed to enable improved management of chronic disease in primary care settings, clinics, and pharmacies. This system offers an extensive test menu including HbA1c, full lipid panel, urine albumin/creatinine, PT/INR, CRP, glucose and creatinine/eGFR.
“The need for this new subsidiary was driven by the widespread adoption of Nova’s BioProfile FLEX2 series of cell culture analyzers and the launch of new clinical products in Benelux, Customers will benefit from having Nova Biomedical sales and support professionals close at hand. Furthermore, from this strategic subsidiary we can better support expansion into the local clinical market,” said Andy O’Toole, Nova’s Vice President European Operations.
About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacture of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova’s BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Benelux, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Taiwan.